Incomplete-penetrant hypertrophic cardiomyopathy MYH7 G256E mutation causes hypercontractility and elevated mitochondrial respiration.

Determining the pathogenicity of hypertrophic cardiomyopathy-associated mutations in the β-myosin heavy chain (MYH7) can be challenging due to its variable penetrance and clinical severity. This study investigates the early pathogenic effects of the incomplete-penetrant MYH7 G256E mutation on myosin function that may trigger pathogenic adaptations and hypertrophy. We hypothesized that the G256E mutation would alter myosin biomechanical function, leading to changes in cellular functions. We developed a collaborative pipeline to characterize myosin function across protein, myofibril, cell, and tissue levels to determine the multiscale effects on structure-function of the contractile apparatus and its implications for gene regulation and metabolic state. The G256E mutation disrupts the transducer region of the S1 head and reduces the fraction of myosin in the folded-back state by 33%, resulting in more myosin heads available for contraction. Myofibrils from gene-edited MYH7WT/G256E human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) exhibited greater and faster tension development. This hypercontractile phenotype persisted in single-cell hiPSC-CMs and engineered heart tissues. We demonstrated consistent hypercontractile myosin function as a primary consequence of the MYH7 G256E mutation across scales, highlighting the pathogenicity of this gene variant. Single-cell transcriptomic and metabolic profiling demonstrated upregulated mitochondrial genes and increased mitochondrial respiration, indicating early bioenergetic alterations. This work highlights the benefit of our multiscale platform to systematically evaluate the pathogenicity of gene variants at the protein and contractile organelle level and their early consequences on cellular and tissue function. We believe this platform can help elucidate the genotype-phenotype relationships underlying other genetic cardiovascular diseases.

[1]  B. Molenaar,et al.  Single-cell transcriptomics provides insights into hypertrophic cardiomyopathy. , 2022, Cell reports.

[2]  D. Mack,et al.  Full-length dystrophin deficiency leads to contractile and calcium transient defects in human engineered heart tissues , 2022, Journal of tissue engineering.

[3]  Gabriela V. Greenland,et al.  Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy , 2021, Scientific Reports.

[4]  C. Ramachandra,et al.  Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes , 2021, Cardiovascular research.

[5]  Christopher N Toepfer,et al.  Cardiac myosin super relaxation (SRX): a perspective on fundamental biology, human disease and therapeutics , 2021, Biology Open.

[6]  V. Daggett,et al.  Modulation of post-powerstroke dynamics in myosin II by 2'-deoxy-ADP. , 2020, Archives of biochemistry and biophysics.

[7]  J. Spudich,et al.  Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state , 2020, Proceedings of the National Academy of Sciences.

[8]  C. Denning,et al.  Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics , 2020, Journal of molecular and cellular cardiology.

[9]  J. Spudich,et al.  The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin , 2020, Science Advances.

[10]  Clifford A. Meyer,et al.  Lisa: inferring transcriptional regulators through integrative modeling of public chromatin accessibility and ChIP-seq data , 2020, Genome Biology.

[11]  Joe Z. Zhang,et al.  Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients. , 2019, European heart journal.

[12]  J. Spudich,et al.  β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity , 2019, Nature Communications.

[13]  S. Sadayappan,et al.  Cardiac myosin binding protein-C phosphorylation regulates the super-relaxed state of myosin , 2019, Proceedings of the National Academy of Sciences.

[14]  Valerie Daggett,et al.  Visualizing Protein Folding and Unfolding. , 2019, Journal of molecular biology.

[15]  Melissa C. Hendershott,et al.  Fluorescent Gene Tagging of Transcriptionally Silent Genes in hiPSCs , 2019, Stem cell reports.

[16]  Yu-Sheng Chen,et al.  A Contraction Stress Model of Hypertrophic Cardiomyopathy due to Sarcomere Mutations , 2018, Stem cell reports.

[17]  Deok‐Ho Kim,et al.  Novel Adult-Onset Systolic Cardiomyopathy Due to MYH7 E848G Mutation in Patient-Derived Induced Pluripotent Stem Cells , 2018, JACC. Basic to translational science.

[18]  H. Aburatani,et al.  Cardiomyocyte gene programs encoding morphological and functional signatures in cardiac hypertrophy and failure , 2018, Nature Communications.

[19]  K. Trybus,et al.  Hypertrophic cardiomyopathy R403Q mutation in rabbit β-myosin reduces contractile function at the molecular and myofibrillar levels , 2018, Proceedings of the National Academy of Sciences.

[20]  C. Don,et al.  Human ESC-Derived Cardiomyocytes Restore Function in Infarcted Hearts of Non-Human Primates , 2018, Nature Biotechnology.

[21]  N. Sniadecki,et al.  Afterload promotes maturation of human induced pluripotent stem cell derived cardiomyocytes in engineered heart tissues. , 2018, Journal of molecular and cellular cardiology.

[22]  J. Spudich,et al.  The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations , 2017, Nature Structural &Molecular Biology.

[23]  J. Seidman,et al.  A Tension-Based Model Distinguishes Hypertrophic versus Dilated Cardiomyopathy , 2016, Cell.

[24]  M. Regnier,et al.  Isolation and Mechanical Measurements of Myofibrils from Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes , 2016, Stem cell reports.

[25]  Christine E. Seidman,et al.  A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice , 2016, Science.

[26]  Deepak Srivastava,et al.  Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness , 2015, Proceedings of the National Academy of Sciences.

[27]  C. Lim,et al.  Targeted inhibition of ANKRD1 disrupts sarcomeric ERK-GATA4 signal transduction and abrogates phenylephrine-induced cardiomyocyte hypertrophy. , 2015, Cardiovascular research.

[28]  B. Maron,et al.  New perspectives on the prevalence of hypertrophic cardiomyopathy. , 2015, Journal of the American College of Cardiology.

[29]  Matthew S. Lebo,et al.  Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity , 2015, Genetics in Medicine.

[30]  Lei Yang,et al.  Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells , 2014, Cardiovascular research.

[31]  A. McCulloch,et al.  PKA phosphorylation of cardiac troponin I modulates activation and relaxation kinetics of ventricular myofibrils. , 2014, Biophysical journal.

[32]  C. Poggesi,et al.  Faster cross‐bridge detachment and increased tension cost in human hypertrophic cardiomyopathy with the R403Q MYH7 mutation , 2014, The Journal of physiology.

[33]  S. Heymans,et al.  Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. , 2013, Cardiovascular research.

[34]  Jonathan P. Davis,et al.  Tropomyosin Ser-283 pseudo-phosphorylation slows myofibril relaxation. , 2013, Archives of biochemistry and biophysics.

[35]  L. Leinwand,et al.  Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function , 2013, Proceedings of the National Academy of Sciences.

[36]  Euan A Ashley,et al.  Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. , 2013, Cell stem cell.

[37]  Andrew L. Miller,et al.  Calcium signaling in cardiac myocytes. , 2011, Cold Spring Harbor perspectives in biology.

[38]  Chiara Tesi,et al.  Sarcomeric determinants of striated muscle relaxation kinetics , 2005, Pflügers Archiv.

[39]  Anne Houdusse,et al.  Three myosin V structures delineate essential features of chemo‐mechanical transduction , 2004, The EMBO journal.

[40]  J. Leiden,et al.  Phosphorylation of Troponin I by Protein Kinase A Accelerates Relaxation and Crossbridge Cycle Kinetics in Mouse Ventricular Muscle , 2001, Circulation research.

[41]  Frederick J. Schoen,et al.  A Mouse Model of Familial Hypertrophic Cardiomyopathy , 1996, Science.

[42]  Howard A. Rockman,et al.  Clinical Medicine , 1915, The Indian Medical Gazette.

[43]  L. Leinwand,et al.  Contractility parameters of human b-cardiac myosin with the hypertrophic cardiomyopathy mutation R403Q show loss of motor function , 2015 .

[44]  M. Regnier,et al.  Calcium binding kinetics of troponin C strongly modulate cooperative activation and tension kinetics in cardiac muscle. , 2011, Journal of molecular and cellular cardiology.

[45]  D. Szczesna‐Cordary,et al.  Regulatory light chain mutations associated with cardiomyopathy affect myosin mechanics and kinetics. , 2009, Journal of molecular and cellular cardiology.